Trial Profile

Relative Bioavailability of BI 1810631 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-way Crossover Trial)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zongertinib (Primary)
Indications Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Boehringer Ingelheim

Most Recent Events

30 Apr 2025 Results (n=16) comparing the relative bioavailability of a single 240-mg dose of zongertinib in spray-dried dispersion formulation delivered orally in fed and fasted conditions presented at the 116th Annual Meeting of the American Association for Cancer Research.
02 Jan 2024 Status changed from active, no longer recruiting to completed.
27 Nov 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com